Symbols / NVNO
NVNO Chart
About
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 7.64M |
| Enterprise Value | -23.52M | Income | -21.96M | Sales | — |
| Book/sh | 50.98 | Cash/sh | 53.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | 37 | IPO | — |
| P/E | — | Forward P/E | -9.79 | PEG | — |
| P/S | — | P/B | 0.23 | P/C | — |
| EV/EBITDA | 1.02 | EV/Sales | — | Quick Ratio | 12.90 |
| Current Ratio | 13.12 | Debt/Eq | 2.69 | LT Debt/Eq | — |
| EPS (ttm) | -37.80 | EPS next Y | -1.19 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-07-31 16:00 | ROA | -35.12% |
| ROE | -57.19% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 655.00K |
| Shs Float | 417.49K | Short Float | 10.46% | Short Ratio | 2.58 |
| Short Interest | — | 52W High | 196.70 | 52W Low | 8.67 |
| Beta | 1.10 | Avg Volume | 20.32K | Volume | 1.04K |
| Target Price | — | Recom | None | Prev Close | $11.50 |
| Price | $11.65 | Change | 1.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$11.65
Latest analyst target
3. DCF / Fair value
$-271.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.65
Low
—
High
—
Mean
—
- What enVVeno's 1-for-35 reverse stock split means for shareholders in 2026 - Stock Titan hu, 15 Jan 2026 08
- enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Register-Guard ue, 24 Feb 2026 18
- enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Holland Sentinel Wed, 25 Feb 2026 06
- enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement - Oak Ridger ue, 24 Feb 2026 20
- enVVeno Medical Announces Reverse Stock Split - El Paso Times hu, 12 Feb 2026 06
- enVVeno Medical (NASDAQ: NVNO): FDA upholds VenoValve PMA not-approvable on appeal - Stock Titan hu, 13 Nov 2025 08
- NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve - Yahoo Finance Mon, 25 Aug 2025 07
- $NVNO stock is down 40% today. Here's what we see in our data. - Quiver Quantitative Fri, 14 Nov 2025 08
- Novel Venous Valve Device for 3.5M CVI Patients: enVVeno Challenges FDA Decision on VenoValve - Stock Titan Mon, 15 Sep 2025 07
- Insider Buyers Lose Additional US$294k As enVVeno Medical Dips To US$6.5m - Yahoo Finance Sat, 22 Nov 2025 08
- Insider Buyers Lose US$294k As enVVeno Medical Sheds US$1.9m - simplywall.st Sat, 22 Nov 2025 08
- FDA Rejects First-Ever Surgical Venous Valve Treatment: enVVeno's VenoValve Hits Regulatory Roadblock - Stock Titan Wed, 20 Aug 2025 07
- Can NVNO stock hit analyst price targets - Trade Ideas & Reliable Trade Execution Plans - mfd.ru Sat, 21 Feb 2026 20
- enVVeno Medical stock plunges after FDA upholds rejection of VenoValve - Investing.com Fri, 14 Nov 2025 08
- enVVeno Medical Announces Reverse Stock Split - Knoxville News Sentinel hu, 15 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4900 | 1742 | — | Sale at price 0.36 per share. | DUHAY FRANCIS | Director | — | 2025-12-11 00:00:00 | D |
| 1 | 4900 | 4067 | — | Sale at price 0.83 per share. | DUHAY FRANCIS | Director | — | 2025-09-15 00:00:00 | D |
| 2 | 81433 | 249999 | — | Purchase at price 3.07 per share. | DUHAY FRANCIS | Director | — | 2024-12-31 00:00:00 | D |
| 3 | 3500 | 10290 | — | Purchase at price 2.94 per share. | GRAY ROBERT | Director | — | 2024-12-31 00:00:00 | D |
| 4 | 5400 | 15660 | — | Purchase at price 2.90 per share. | SHRIVASTAVA SANJAY | Director | — | 2024-12-24 00:00:00 | D |
| 5 | 12000 | 30600 | — | Purchase at price 2.55 per share. | BERMAN ROBERT ANDREW | Chief Executive Officer | — | 2024-12-19 00:00:00 | D |
| 6 | 9620 | 24339 | — | Purchase at price 2.53 per share. | JENUSAITIS MATTHEW | Director | — | 2024-12-19 00:00:00 | D |
| 7 | 8334 | 29919 | — | Conversion of Exercise of derivative security at price 3.59 per share. | ALAVI HAMED | Chief Technology Officer | — | 2024-03-13 00:00:00 | D |
| 8 | 8334 | 51837 | — | Sale at price 6.22 per share. | ALAVI HAMED | Chief Technology Officer | — | 2024-03-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -24.92M | -26.23M | -24.51M | -16.75M |
| TotalUnusualItems | 1.62M | 1.54M | 102.00K | 313.00K |
| TotalUnusualItemsExcludingGoodwill | 1.62M | 1.54M | 102.00K | 313.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -21.82M | -23.52M | -24.67M | -16.53M |
| ReconciledDepreciation | 528.00K | 546.00K | 525.00K | 453.00K |
| EBITDA | -23.30M | -24.69M | -24.41M | -16.44M |
| EBIT | -23.83M | -25.24M | -24.93M | -16.89M |
| NetInterestIncome | 389.00K | 180.00K | 161.00K | 19.00K |
| InterestIncome | 389.00K | 180.00K | 161.00K | 19.00K |
| NormalizedIncome | -23.44M | -25.06M | -24.77M | -16.84M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -21.82M | -23.52M | -24.67M | -16.53M |
| TotalExpenses | 23.83M | 25.24M | 24.93M | 16.89M |
| TotalOperatingIncomeAsReported | -23.83M | -25.24M | -24.93M | -16.89M |
| DilutedAverageShares | 489.77K | 351.46K | 320.86K | 248.00K |
| BasicAverageShares | 489.77K | 351.46K | 320.86K | 248.00K |
| DilutedEPS | -44.45 | -66.85 | -77.00 | -66.50 |
| BasicEPS | -44.45 | -66.85 | -77.00 | -66.50 |
| DilutedNIAvailtoComStockholders | -21.82M | -23.52M | -24.67M | -16.53M |
| NetIncomeCommonStockholders | -21.82M | -23.52M | -24.67M | -16.53M |
| NetIncome | -21.82M | -23.52M | -24.67M | -16.53M |
| NetIncomeIncludingNoncontrollingInterests | -21.82M | -23.52M | -24.67M | -16.53M |
| NetIncomeContinuousOperations | -21.82M | -23.52M | -24.67M | -16.53M |
| PretaxIncome | -21.82M | -23.52M | -24.67M | -16.53M |
| OtherIncomeExpense | 1.62M | 1.54M | 102.00K | 346.00K |
| OtherNonOperatingIncomeExpenses | 33.00K | |||
| SpecialIncomeCharges | 0.00 | 313.00K | ||
| OtherSpecialCharges | -313.00K | |||
| GainOnSaleOfSecurity | 1.62M | 1.54M | 102.00K | |
| NetNonOperatingInterestIncomeExpense | 389.00K | 180.00K | 161.00K | 19.00K |
| TotalOtherFinanceCost | -18.71K | |||
| InterestIncomeNonOperating | 389.00K | 180.00K | 161.00K | 19.00K |
| OperatingIncome | -23.83M | -25.24M | -24.93M | -16.89M |
| OperatingExpense | 23.83M | 25.24M | 24.93M | 16.89M |
| ResearchAndDevelopment | 12.25M | 13.58M | 9.91M | 5.73M |
| SellingGeneralAndAdministration | 11.58M | 11.65M | 15.02M | 11.16M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 501.03K | 380.49K | 270.63K | 270.57K |
| ShareIssued | 501.03K | 380.49K | 270.63K | 270.57K |
| TotalDebt | 1.06M | 1.40M | 1.72M | 2.01M |
| TangibleBookValue | 42.16M | 46.20M | 38.73M | 54.40M |
| InvestedCapital | 42.16M | 46.20M | 38.73M | 54.40M |
| WorkingCapital | 41.64M | 45.55M | 37.91M | 53.46M |
| NetTangibleAssets | 42.16M | 46.20M | 38.73M | 54.40M |
| CapitalLeaseObligations | 1.06M | 1.40M | 1.72M | 2.01M |
| CommonStockEquity | 42.16M | 46.20M | 38.73M | 54.40M |
| TotalCapitalization | 42.16M | 46.20M | 38.73M | 54.40M |
| TotalEquityGrossMinorityInterest | 42.16M | 46.20M | 38.73M | 54.40M |
| StockholdersEquity | 42.16M | 46.20M | 38.73M | 54.40M |
| RetainedEarnings | -151.85M | -130.04M | -106.52M | -81.85M |
| AdditionalPaidInCapital | 194.01M | 176.24M | 145.25M | 136.25M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.79M | 2.44M | 2.93M | 3.29M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 700.00K | 1.06M | 1.40M | 1.72M |
| LongTermDebtAndCapitalLeaseObligation | 700.00K | 1.06M | 1.40M | 1.72M |
| LongTermCapitalLeaseObligation | 700.00K | 1.06M | 1.40M | 1.72M |
| CurrentLiabilities | 2.10M | 1.37M | 1.53M | 1.58M |
| OtherCurrentLiabilities | 121.00K | 128.00K | 177.00K | 60.00K |
| CurrentDebtAndCapitalLeaseObligation | 364.00K | 338.00K | 314.00K | 291.00K |
| CurrentCapitalLeaseObligation | 364.00K | 338.00K | 314.00K | 291.00K |
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 604.00K | 478.00K | 391.00K | 525.00K |
| PayablesAndAccruedExpenses | 1.01M | 427.00K | 648.00K | 704.00K |
| CurrentAccruedExpenses | 118.00K | 144.00K | ||
| Payables | 1.01M | 427.00K | 648.00K | 560.00K |
| AccountsPayable | 1.01M | 427.00K | 648.00K | 560.00K |
| TotalAssets | 44.95M | 48.63M | 41.66M | 57.70M |
| TotalNonCurrentAssets | 1.22M | 1.71M | 2.23M | 2.66M |
| OtherNonCurrentAssets | 31.00K | 31.00K | 54.00K | |
| NonCurrentPrepaidAssets | 31.00K | 31.00K | 31.00K | 54.00K |
| NetPPE | 1.19M | 1.68M | 2.19M | 2.60M |
| AccumulatedDepreciation | -1.26M | -1.07M | -849.00K | -637.00K |
| GrossPPE | 2.45M | 2.75M | 3.04M | 3.24M |
| Leases | 213.00K | 193.00K | ||
| OtherProperties | 1.57M | 1.90M | 2.20M | 2.51M |
| MachineryFurnitureEquipment | 873.00K | 855.00K | 846.00K | 539.00K |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 43.73M | 46.92M | 39.44M | 55.04M |
| OtherCurrentAssets | 581.00K | 511.00K | 392.00K | 312.00K |
| PrepaidAssets | 312.35K | |||
| CashCashEquivalentsAndShortTermInvestments | 43.15M | 46.41M | 39.04M | 54.73M |
| OtherShortTermInvestments | 41.40M | 42.79M | 34.49M | 0.00 |
| CashAndCashEquivalents | 1.75M | 3.62M | 4.55M | 54.73M |
| CashFinancial | 54.73M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.88M | -18.89M | -15.73M | -12.22M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 13.59M | 25.79M | 0.00 | 57.36M |
| CapitalExpenditure | -37.00K | -33.00K | -115.00K | -368.00K |
| InterestPaidSupplementalData | 0.00 | |||
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 1.75M | 3.62M | 4.55M | 54.73M |
| BeginningCashPosition | 3.62M | 4.55M | 54.73M | 9.34M |
| ChangesInCash | -1.87M | -935.00K | -50.17M | 45.39M |
| FinancingCashFlow | 13.64M | 25.79M | 0.00 | 57.61M |
| CashFlowFromContinuingFinancingActivities | 13.64M | 25.79M | 0.00 | 57.61M |
| ProceedsFromStockOptionExercised | 46.00K | 0.00 | 0.00 | 245.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 13.59M | 25.79M | 0.00 | 57.36M |
| CommonStockIssuance | 13.59M | 25.79M | 0.00 | 57.36M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 1.33M | -7.87M | -34.55M | -368.00K |
| CashFlowFromContinuingInvestingActivities | 1.33M | -7.87M | -34.55M | -368.00K |
| NetInvestmentPurchaseAndSale | 1.37M | -7.83M | -34.44M | 0.00 |
| SaleOfInvestment | 56.94M | 48.69M | 13.69M | 0.00 |
| PurchaseOfInvestment | -55.57M | -56.52M | -48.13M | 0.00 |
| NetPPEPurchaseAndSale | -37.00K | -33.00K | -115.00K | -368.00K |
| PurchaseOfPPE | -37.00K | -33.00K | -115.00K | -368.00K |
| OperatingCashFlow | -16.84M | -18.86M | -15.62M | -11.85M |
| CashFlowFromContinuingOperatingActivities | -16.84M | -18.86M | -15.62M | -11.85M |
| ChangeInWorkingCapital | 290.00K | -616.00K | -420.00K | -1.15M |
| ChangeInOtherCurrentLiabilities | -338.00K | -314.00K | -290.00K | |
| ChangeInPayablesAndAccruedExpense | 698.00K | -183.00K | -73.00K | -1.08M |
| ChangeInAccruedExpense | 38.00K | -161.00K | -250.00K | |
| ChangeInPayable | -221.00K | 88.00K | -833.00K | |
| ChangeInAccountPayable | -221.00K | 88.00K | -833.00K | |
| ChangeInPrepaidAssets | -70.00K | -119.00K | -57.00K | -63.00K |
| OtherNonCashItems | -290.00K | -313.00K | ||
| StockBasedCompensation | 4.14M | 5.20M | 8.99M | 6.00M |
| UnrealizedGainLossOnInvestmentSecurities | 22.00K | -468.00K | -49.00K | 0.00 |
| DepreciationAmortizationDepletion | 528.00K | 546.00K | 525.00K | 453.00K |
| DepreciationAndAmortization | 528.00K | 546.00K | 525.00K | 453.00K |
| Depreciation | 528.00K | 546.00K | 525.00K | 453.00K |
| OperatingGainsLosses | -313.00K | |||
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -21.82M | -23.52M | -24.67M | -16.53M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NVNO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|